Few medicines have entered popular culture as quickly as Ozempic. What began as a prescription treatment for type 2 diabetes has become a global phenomenon, discussed by celebrities, entrepreneurs, doctors and millions of people trying to understand a new generation of weight-loss medications.

The fascination is understandable. Semaglutide, the active ingredient in Ozempic, can produce substantial weight loss in people with overweight or obesity. In a landmark clinical trial, participants receiving the higher 2.4 mg dose of semaglutide alongside lifestyle intervention lost an average of 14.9% of their body weight after 68 weeks, compared with 2.4% among those receiving placebo.

But the real story is more interesting than the numbers. These medicines have changed the way scientists and the public think about hunger itself. They have also raised difficult questions about long-term treatment, side effects, weight regain and whether society is beginning to medicalise something that was once viewed primarily as a matter of willpower.

What Exactly Is Ozempic?

First, an important distinction.

Ozempic is a brand name for semaglutide and is approved for adults with type 2 diabetes, alongside diet and exercise, including to reduce the risk of certain major cardiovascular events in people with type 2 diabetes and established cardiovascular disease. The higher-dose semaglutide product used specifically for chronic weight management is marketed as Wegovy.

Both contain the same active ingredient, but they have different approved uses and dosing regimens. That distinction has become increasingly important as social media has turned “Ozempic” into a catch-all term for the entire GLP-1 weight-loss phenomenon.

Semaglutide belongs to a class of medicines called GLP-1 receptor agonists. GLP-1 is a hormone naturally produced by the body after eating. It helps regulate blood glucose and slows the movement of food through the digestive system, contributing to a feeling of fullness. GLP-1 receptors are also found in areas of the brain involved in appetite regulation.

The result is relatively simple: people tend to feel less hungry, feel full sooner and consume less food. That simplicity is part of what makes the science so significant.

It Doesn’t Simply “Burn Fat”

One of the most persistent misconceptions about Ozempic is that it somehow melts fat away. It doesn’t.

Semaglutide’s weight-loss effect is primarily related to reduced energy intake resulting from decreased appetite and increased satiety. In the STEP 1 trial, researchers reported that weight loss was associated with reductions in appetite and food intake, alongside improvements in several cardiometabolic measures.

In other words, the medication changes the biological signals that influence how much people want to eat.

This matters because obesity has increasingly come to be understood as a chronic disease involving complex interactions between genetics, hormones, environment, behaviour and metabolism. The idea that someone should simply “eat less and exercise more” overlooks the biological systems that make maintaining weight loss so difficult for many people.

GLP-1 medicines do not eliminate those complexities, but they intervene in one of the systems that regulates them.

How Much Weight Can People Actually Lose?

The results from clinical trials are impressive, but they need to be understood properly.

In the 68-week STEP 1 trial, adults with obesity, or overweight plus at least one weight-related condition, received weekly semaglutide 2.4 mg alongside lifestyle intervention. Average weight loss was 14.9%, compared with 2.4% with placebo. More than half of participants receiving semaglutide lost at least 15% of their initial body weight.

For someone weighing 100 kilograms, a 15% reduction would represent approximately 15 kilograms.

That is clinically meaningful rather than simply cosmetic. Weight loss of this magnitude can improve several obesity-related health measures, including blood pressure, blood glucose and physical functioning. The STEP 1 researchers observed improvements in several cardiometabolic risk factors among participants receiving semaglutide.

However, clinical trials are not the same as celebrity testimonials. Participants are carefully selected, monitored and supported, and individual results vary considerably.

There is no guarantee that someone taking semaglutide will lose 15% of their body weight.

The Problem Nobody Likes to Talk About

Perhaps the most important question is not what happens while taking semaglutide. It is what happens when you stop.

In a follow-up study of participants from STEP 1, researchers found that people regained a substantial proportion of the weight they had lost after semaglutide was discontinued. One year after stopping treatment, participants had regained approximately two-thirds of their previous weight loss on average. Some health improvements also moved back towards baseline.

This finding is not evidence that semaglutide “doesn’t work.” Quite the opposite: it demonstrates how strongly biological regulation of body weight can reassert itself when treatment is removed.

It also challenges the popular idea that these medications are simply a temporary shortcut to a permanently lower weight.

For many patients, obesity treatment may need to be approached as a long-term medical issue rather than a short-term diet. The weight-regain findings from semaglutide research have strengthened that argument.

What About Side Effects?

The extraordinary popularity of GLP-1 medicines can sometimes make them sound safer and simpler than they really are.

The most common adverse effects associated with semaglutide are gastrointestinal, including nausea, diarrhoea, vomiting and constipation. In the STEP 1 trial, gastrointestinal effects were generally mild to moderate and tended to improve over time, although some participants discontinued treatment because of them.

There are also more serious risks and contraindications that require medical assessment. US prescribing information includes warnings concerning conditions such as pancreatitis, gallbladder disease, kidney injury and serious hypersensitivity reactions, among others. Semaglutide products also carry important contraindications relating to certain thyroid cancer risks.

This is why the idea of obtaining GLP-1 medicines through informal online channels or using someone else’s prescription is particularly concerning. These are prescription medicines with real physiological effects, not lifestyle supplements.

Has Ozempic Changed the Way We Think About Obesity?

Perhaps its greatest impact is cultural.

For decades, excess weight was frequently discussed in moral terms. People were told they lacked discipline, ate too much or simply needed to exercise more.

The success of GLP-1 medications has made that explanation increasingly difficult to defend.

If manipulating a biological pathway can dramatically alter appetite and body weight, it becomes harder to argue that weight is determined purely by personal choices. Behaviour still matters enormously, but behaviour operates within a biological system.

This does not mean lifestyle is irrelevant. In clinical trials, semaglutide has generally been studied alongside dietary and physical-activity interventions rather than as a replacement for them.

Instead, the emergence of GLP-1 medicines suggests that the old distinction between “willpower” and “biology” was probably too simplistic all along.

The Celebrity Problem

The cultural phenomenon surrounding Ozempic has created another problem.

When a prescription medicine becomes fashionable among celebrities and influencers, its medical purpose can disappear beneath the glamour.

Weight loss becomes a lifestyle trend. “Ozempic face” becomes a social-media talking point. People who have never been diagnosed with obesity begin discussing injections as though they were simply another wellness product.

But obesity is a complex chronic disease, and semaglutide is a prescription medicine—not a cosmetic treatment designed for anyone who wants to lose a few kilograms.

That distinction matters, particularly when social media encourages people to compare their bodies and seek increasingly rapid transformations.

What Comes Next?

Ozempic may ultimately be remembered not as the end of the weight-loss story, but as the beginning of a new chapter.

The field is developing rapidly, with new GLP-1-based treatments, combination medicines and different formulations being investigated and approved. In March 2026, the US FDA approved a higher 7.2 mg dose of Wegovy for long-term weight reduction and maintenance in certain adults with obesity or overweight plus a weight-related condition.

The direction of travel is clear: medicines that influence appetite and metabolism are becoming increasingly sophisticated.

The bigger question is how society will use them.

A New Understanding of Weight

The most important lesson from the Ozempic era may have little to do with celebrity culture or rapid weight loss.

It may be that we are finally developing a more sophisticated understanding of obesity.

Human appetite is not simply a matter of choice. Hunger is regulated by an extraordinarily complex network involving the brain, hormones, metabolism, environment and behaviour. Semaglutide works because it interacts with part of that system.

That does not make it a miracle drug, nor does it make lifestyle habits irrelevant. It makes it a powerful medical tool with significant benefits, meaningful risks and limitations that deserve to be understood.

The future of weight management is unlikely to be about choosing between medicine and healthy living. It will increasingly be about understanding how the two can work together.

And that may be the most important change Ozempic has brought about—not simply changing how quickly some people can lose weight, but changing the way we think about why losing it was ever so difficult in the first place.

Further Reading

The Best Foods for Brain Health

Stay Connected

Subscribe to the Together Magazine newsletter for thoughtful features, personal development insights, cultural recommendations, museum exhibitions, events in Brussels and Belgium, and the latest stories delivered directly to your inbox.

The post Ozempic: The Drug That Changes How We Think About Weight Loss appeared first on Together Magazine.

​